Compare Biogen Inc (BIIB) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.6. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | VIG | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | — |
52-Week High | $216.63 | $239.03 |
52-Week Low | $122.68 | $204.09 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
VIG trades at $238.48, down 0.15% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF shows strong institutional support and consistent dividend growth, with a recent $1.00 dividend declared for June 2026. Current price sits near key support at $238, with resistance at $239.
The outlook remains positive given VIG's focus on dividend growth stocks and low expense ratio. Key risks include market volatility and interest rate sensitivity, but the ETF's quality holdings provide defensive characteristics during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
